Cited by

• Clinical impact of primary tumor sidedness and sex on unresectable post-recurrence survival in resected pathological stage II-III colorectal cancers: a nationwide multicenter retrospective study.

  Abe S, Kawai K, Nozawa H, Sasaki K, Murono K, Emoto S, Ozawa T, Yokoyama Y, Nagai Y, Anzai H, Sonoda H, Yamauchi S, Sugihara K, Ishihara S. Abe S, et al. BMC Cancer. 2022 May 2;22(1):486. doi: 10.1186/s12885-022-09615-z. BMC Cancer. 2022. PMID: 35501727 Free PMC article.
• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.

  Chan DLH, Segelov E, Wong RS, Smith A, Herbertson RA, Li BT, Tebbutt N, Price T, Pavlakis N. Chan DLH, et al. Cochrane Database Syst Rev. 2017 Jun 27;6(6):CD007047. doi: 10.1002/14651858.CD007047.pub2. Cochrane Database Syst Rev. 2017. PMID: 28654140 Free PMC article.
• Is the Location of the Tumor Another Prognostic Factor for Patients With Colon Cancer?

  Jung MK, Shin US, Ki YJ, Kim YB, Moon SM, Sung SJ. Jung MK, et al. Ann Coloproctol. 2017 Dec;33(6):210-218. doi: 10.3393/ac.2017.33.6.210. Epub 2017 Dec 31. Ann Coloproctol. 2017. PMID: 29354603 Free PMC article.
• Anti-angiogenic therapies for metastatic colorectal cancer.

  Wagner AD, Arnold D, Grothey AA, Haerting J, Unverzagt S. Wagner AD, et al. Cochrane Database Syst Rev. 2009 Jul 8;2009(3):CD005392. doi: 10.1002/14651858.CD005392.pub3. Cochrane Database Syst Rev. 2009. PMID: 19588372 Free PMC article.
• Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review.

  Bachet JB, Peuvrel L, Bachmeyer C, Reguiai Z, Gourraud PA, Bouché O, Ychou M, Bensadoun RJ, Dreno B, André T. Bachet JB, et al. Oncologist. 2012;17(4):555-68. doi: 10.1634/theoncologist.2011-0365. Epub 2012 Mar 16. Oncologist. 2012. PMID: 22426526 Free PMC article.